Authors: Freyer, G Rougier, P Bugat, R Droz, JP Marty, M Bleiberg, H Mignard, D Awad, L Herait, P Culine, S Trillet-Lenoir, V

Citation: G. Freyer et al., Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure, BR J CANC, 83(4), 2000, pp. 431-437

Authors: Van Cutsem, E Cunningham, D Huinink, WWT Punt, CJA Alexopoulos, CG Dirix, L Symann, M Blijham, GH Cholet, P Fillet, G Van Groeningen, C Vannetzel, JM Levi, F Panagos, G Unger, C Wils, J Cote, C Blanc, C Herait, P Bleiberg, H

Citation: E. Van Cutsem et al., Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU), EUR J CANC, 35(1), 1999, pp. 54-59